# Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

> **NCT05468671** · PHASE4 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 34 (actual)

## Conditions studied

- Endobronchial Metastases
- Bronchoesophageal Fistula
- General Anesthetic Drug Adverse Reaction

## Interventions

- **DRUG:** Remimazolam
- **DRUG:** Propofol
- **DRUG:** Rocuronium
- **DRUG:** Remifentanil
- **DRUG:** oxycodone
- **DRUG:** Sugammadex Sodium
- **DRUG:** Flumazenil

## Key facts

- **NCT ID:** NCT05468671
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2021-08-04
- **Final completion:** 2022-09-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468671, "Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05468671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*